Reported Earlier, Edwards Lifesciences RHEIA Trial Discloses TAVI Outcomes for Women With SAPIEN 3 Valves
Author: Benzinga Newsdesk | September 03, 2024 03:31am
Edwards Lifesciences (NYSE:EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation (TAVI). Presenting one-year results during a Hot Line session at the ESC Congress 2024, investigators reported superior outcomes for women receiving the Edwards SAPIEN 3 Ultra or SAPIEN 3 Ultra RESILIA valves as compared to those receiving surgical aortic valve replacement (SAVR).
Posted In: EW